A phase II trial of carboplatin, methotrexate and fluorouracil in fluorouracii-pretreated colorectal cancer

P. Pronzato, F. Botto, E. Ghio, F. Pensa, A. Tognoni, F. Vaira, A. Vigani, E. Neri

Research output: Contribution to journalArticle

Abstract

5-Fluorouracil and leucovorin combination is the most commonly applied chemotherapy treatment for colorectal cancer patients, both in the adjuvant setting and for advanced disease. Patients resistant or refractory to the 5- fluorouracil-leucovorin combination have been treated in this phase II trial with carboplatin plus methotrexate and fluorouracil in sequence. Twenty patients with measurable lesions from advanced colorectal cancer were entered in the trial. The treatment plan was carboplatin 300 mg/m 2 day 1, methotrexate 40 mg/m 2 day 1, fluorouracil 600 mg/m 2 day 2, every 21 days. Two patients with liver metastasis had a partial response. Median survival was 12 months (range 4-24). Toxicity was acceptable and no patient had to be hospitalized because of the treatment. in this set of patients activity of the new combination is marginal.

Original languageEnglish
Pages (from-to)254-257
Number of pages4
JournalJournal of Chemotherapy
Volume10
Issue number3
Publication statusPublished - 1998

Keywords

  • 5-fluorouracil
  • Carboplatin
  • Colorectal cancer
  • Methotrexate

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'A phase II trial of carboplatin, methotrexate and fluorouracil in fluorouracii-pretreated colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Pronzato, P., Botto, F., Ghio, E., Pensa, F., Tognoni, A., Vaira, F., Vigani, A., & Neri, E. (1998). A phase II trial of carboplatin, methotrexate and fluorouracil in fluorouracii-pretreated colorectal cancer. Journal of Chemotherapy, 10(3), 254-257.